138 related articles for article (PubMed ID: 8047295)
1. A detailed anatomical analysis of neurotransmitter receptors in the putamen and caudate in Parkinson's disease and Alzheimer's disease.
Griffiths PD; Perry RH; Crossman AR
Neurosci Lett; 1994 Mar; 169(1-2):68-72. PubMed ID: 8047295
[TBL] [Abstract][Full Text] [Related]
2. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.
Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Burn D; Johnson M; Perry RH; McKeith IG; Ballard C; Perry EK
Brain; 1999 Aug; 122 ( Pt 8)():1449-68. PubMed ID: 10430831
[TBL] [Abstract][Full Text] [Related]
3. Loss of dopamine D2 receptors in Alzheimer's disease with parkinsonism but not Parkinson's or Alzheimer's disease.
Joyce JN; Murray AM; Hurtig HI; Gottlieb GL; Trojanowski JQ
Neuropsychopharmacology; 1998 Dec; 19(6):472-80. PubMed ID: 9803423
[TBL] [Abstract][Full Text] [Related]
4. Neurotransmitter receptor alterations in Parkinson's disease.
Reisine TD; Fields JZ; Yamamura HI
Life Sci; 1977 Aug; 21(3):335-43. PubMed ID: 197361
[No Abstract] [Full Text] [Related]
5. Choline acetytransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment.
Mattila PM; Röyttä M; Lönnberg P; Marjamäki P; Helenius H; Rinne JO
Acta Neuropathol; 2001 Aug; 102(2):160-6. PubMed ID: 11563631
[TBL] [Abstract][Full Text] [Related]
6. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride.
Rinne JO; Laihinen A; Ruottinen H; Ruotsalainen U; Någren K; Lehikoinen P; Oikonen V; Rinne UK
J Neurol Sci; 1995 Oct; 132(2):156-61. PubMed ID: 8543941
[TBL] [Abstract][Full Text] [Related]
7. A post-mortem study on striatal dopamine receptors in Parkinson's disease.
Rinne JO; Laihinen A; Lönnberg P; Marjamäki P; Rinne UK
Brain Res; 1991 Aug; 556(1):117-22. PubMed ID: 1834312
[TBL] [Abstract][Full Text] [Related]
8. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases.
Seeman P; Bzowej NH; Guan HC; Bergeron C; Reynolds GP; Bird ED; Riederer P; Jellinger K; Tourtellotte WW
Neuropsychopharmacology; 1987 Dec; 1(1):5-15. PubMed ID: 2908095
[TBL] [Abstract][Full Text] [Related]
9. Changes in benzodiazepine and acetylcholine receptors in the globus pallidus in Parkinson's disease.
Griffiths PD; Sambrook MA; Perry R; Crossman AR
J Neurol Sci; 1990 Dec; 100(1-2):131-6. PubMed ID: 1965202
[TBL] [Abstract][Full Text] [Related]
10. Does loss of nerve growth factor receptors precede loss of cholinergic neurons in Alzheimer's disease? An autoradiographic study in the human striatum and basal forebrain.
Strada O; Hirsch EC; Javoy-Agid F; Lehéricy S; Ruberg M; Hauw JJ; Agid Y
J Neurosci; 1992 Dec; 12(12):4766-74. PubMed ID: 1464766
[TBL] [Abstract][Full Text] [Related]
11. Muscarinic receptor binding changes in postmortem Parkinson's disease.
McOmish C; Pavey G; McLean C; Horne M; Dean B; Scarr E
J Neural Transm (Vienna); 2017 Feb; 124(2):227-236. PubMed ID: 27873015
[TBL] [Abstract][Full Text] [Related]
12. D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy.
Pierot L; Desnos C; Blin J; Raisman R; Scherman D; Javoy-Agid F; Ruberg M; Agid Y
J Neurol Sci; 1988 Sep; 86(2-3):291-306. PubMed ID: 2975699
[TBL] [Abstract][Full Text] [Related]
13. Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. III. Results in Parkinson's disease cases.
Joyce JN
Brain Res; 1993 Jan; 600(1):156-60. PubMed ID: 8422582
[TBL] [Abstract][Full Text] [Related]
14. The decrease of dopamine D₂/D₃ receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB₁ cannabinoid receptors in Parkinson's disease: a preliminary autoradiographic study with the selective dopamine D₂/D₃ antagonist [³H]raclopride and the novel CB₁ inverse agonist [¹²⁵I]SD7015.
Farkas S; Nagy K; Jia Z; Harkany T; Palkovits M; Donohou SR; Pike VW; Halldin C; Máthé D; Csiba L; Gulyás B
Brain Res Bull; 2012 Apr; 87(6):504-10. PubMed ID: 22421165
[TBL] [Abstract][Full Text] [Related]
15. Coactivation of dopamine D1 and D2 receptors increases the affinity of cholecystokinin-8 receptors in membranes from post-mortem human caudate-putamen.
von Euler G; Mailleux P; von Euler M; Schiffmann SN; Vanderhaeghen JJ; Fuxe K
Brain Res; 1992 Jul; 584(1-2):157-62. PubMed ID: 1325243
[TBL] [Abstract][Full Text] [Related]
16. Reduction in striatal D2 dopamine receptor mRNA and binding following AF64A lesions.
Narang N; Pundt LL; Hunt ME; Alburges ME; Wamsley JK
Mol Chem Neuropathol; 1993 Sep; 20(1):81-96. PubMed ID: 8251034
[TBL] [Abstract][Full Text] [Related]
17. Measurement of dopamine D2-like receptors in postmortem CNS and pituitary: differential regional changes in schizophrenia.
Dean B; Pavey G; Scarr E; Goeringer K; Copolov DL
Life Sci; 2004 May; 74(25):3115-31. PubMed ID: 15081577
[TBL] [Abstract][Full Text] [Related]
18. Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism.
Graham WC; Sambrook MA; Crossman AR
Brain Res; 1993 Feb; 602(2):290-303. PubMed ID: 8095431
[TBL] [Abstract][Full Text] [Related]
19. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum.
Kaufman MJ; Madras BK
Synapse; 1991 Sep; 9(1):43-9. PubMed ID: 1796351
[TBL] [Abstract][Full Text] [Related]
20. Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain.
Madras BK; Gracz LM; Fahey MA; Elmaleh D; Meltzer PC; Liang AY; Stopa EG; Babich J; Fischman AJ
Synapse; 1998 Jun; 29(2):116-27. PubMed ID: 9593102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
